|
T16560 |
Poloxin
|
|
PLK
|
|
Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM). |
|
T3643 |
HMN-176
|
|
PLK
|
|
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1). |
|
T10215 |
AAPK-25
|
|
Apoptosis
,
PLK
,
Aurora Kinase
|
|
|
|
T6217 |
LFM-A13
|
|
PLK
,
JAK
,
BTK
|
|
LFM-A13（IC50=2.5 μM）, a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK. |
|
T15454 |
GW843682X
|
GW843682 |
VEGFR
,
PLK
,
CDK
,
PDGFR
,
Aurora Kinase
|
|
GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM). |
|
T6282 |
GSK461364
|
GSK461364A |
PLK
|
|
GSK461364 (GSK461364A)(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3. |
|
T14927 |
Centrinone
|
LCR-263 |
PLK
,
Aurora Kinase
|
|
Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM). |
|
T1839 |
Mps1-IN-2
|
|
Kinesin
,
PLK
|
|
Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor. |
|
T2634 |
Ro3280
|
RO 3280,Ro5203280 |
PLK
|
|
Ro3280 (Ro5203280) is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM). |
|
T2704 |
MLN0905
|
PLK1 Inhibitor |
PLK
|
|
MLN0905 (PLK1 Inhibitor) is an effective PLK1 inhibitor(IC50=2 nM). |
|
T7200 |
TAK-960
|
|
PLK
|
|
TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively. |
|
T21678 |
3MB-PP1
|
|
PLK
|
|
3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor. In cells expressing analog-sensitive Plk1 alleles, 3MB-PP1 blocks mitotic progression and cell division arise by targeting Plk1. 3MB-PP1 specifi... |
|
T16750 |
Rigosertib
|
ON-01910 |
Apoptosis
,
FLT
,
PLK
,
PI3K
,
Bcr-Abl
,
CDK
,
PDGFR
,
Src
|
|
Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition of the PI3 kina... |
|
T5818 |
Rigosertib sodium
|
Rigosertib,Estybon,ON-01910 |
Apoptosis
,
PLK
,
PI3K
|
|
Rigosertib sodium (ON-01910), a non-ATP-competitive inhibitor of PLK1(IC50=9 nM), exhibits 30-fold higher specificity activity over Plk2 and no effect on Plk3. |
|
T2438 |
HMN-214
|
IVX-214,HMN214 |
PLK
|
|
HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM. |
|
T6247 |
Onvansertib
|
NMS-P937,NMS-1286937 |
Apoptosis
,
PLK
|
|
Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3. |
|
T19664 |
ON1231320
|
GBO-006 |
Apoptosis
,
PLK
|
|
ON1231320 (GBO-006) is a Polo-like kinase 2 (PLK2) inhibitor. |
|
T6283 |
Wortmannin
|
SL-2052,KY-12420 |
ATM/ATR
,
DNA-PK
,
Serine/threonin kinase
,
PLK
,
PI3K
,
Antibiotic
,
Autophagy
|
|
Wortmannin (SL-2052) is a PI3K inhibitor (IC50=3 nM) that is covalent and irreversible. Wortmannin is also an inhibitor of PlK1 and PlK3 (IC50=5.8/48 nM) that blocks autophagy. |
|
T22288 |
(1E)-CFI-400437 dihydrochloride
|
CFI-400437 dihydrochloride |
PLK
|
|
(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) is a selective and potent polo-like kinase 4 (PLK4) inhibitor. |
|
T2271 |
SBE13 Hydrochloride
|
SBE 13 hydrochloride,SBE 13 HCl |
Apoptosis
,
PLK
,
Autophagy
|
|
SBE13 Hydrochloride (SBE 13 HCl) is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2/3. |
|
T6019 |
Volasertib
|
BI 6727 |
Apoptosis
,
PLK
|
|
Volasertib (BI 6727) (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM). |
|
T6173 |
BI 2536
|
|
Apoptosis
,
Epigenetic Reader Domain
,
PLK
|
|
BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3. |
|
T40507 |
BTO-1
|
|
|
|
BTO-1 is a compound known as a Polo-like kinase (Plk) inhibitor, commonly employed for its effectiveness in regulating processes involving phosphorylation and dephosphorylation. |
|
T73449 |
CZS-241
|
|
|
|
CZS-241 is an orally active, selective Polo-like Kinase (PLK) 4 inhibitor with an IC 50 of 2.6 nM that also inhibits TRKA at an IC 50 of 2.74 μM. It induces apoptosis and causes cell cycle arrest at the S/G2 phase, demon... |
